SBRA logo

Sabra Health Care REIT, Inc. Stock Price

NasdaqGS:SBRA Community·US$5.2b Market Cap
  • 1 Narratives written by author
  • 1 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author

SBRA Share Price Performance

US$20.72
3.28 (18.81%)
US$22.00
Fair Value
US$20.72
3.28 (18.81%)
5.8% undervalued intrinsic discount
US$22.00
Fair Value
Price US$20.72
AnalystConsensusTarget US$22.00

SBRA Community Narratives

·
Fair Value US$22 5.8% undervalued intrinsic discount

US Senior Living Demand Will Unlock Future Value

0users have liked this narrative
1users have commented on this narrative
8users have followed this narrative
US$22
5.8% undervalued intrinsic discount
Revenue
15.59% p.a.
Profit Margin
20.3%
Future PE
33.95x
Price in 2029
US$27.52

Trending Discussion

Updated Narratives

SBRA logo

SBRA: Occupancy Trends And Development Discipline Will Shape Confidence In 2026 Outlook

Fair Value: US$22 5.8% undervalued intrinsic discount
8 users have set this as their fair value
1 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Good value average dividend payer.

2 Risks
3 Rewards

Sabra Health Care REIT, Inc. Key Details

US$815.7m

Revenue

US$295.7m

Cost of Revenue

US$519.9m

Gross Profit

US$363.8m

Other Expenses

US$156.2m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
0.62
63.74%
19.15%
95.6%
View Full Analysis

About SBRA

Founded
2010
Employees
58
CEO
Richard Matros
WebsiteView website
www.sabrahealth.com

Sabra Health Care REIT, Inc. operates as a self-administered, self-managed real estate investment trust that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout the United States and Canada. Sabra Health Care REIT, Inc. is incorporated on May 10th, 2010 and is based in Tustin, United States.

Recent SBRA News & Updates

Seeking Alpha May 17

Sabra Health Care REIT A Buy, As Q1 Results Show Portfolio Growth

Summary Sabra Health Care REIT is rated a buy, reflecting portfolio growth, reasonable valuation, and robust geographic diversification. SBRA demonstrates strong revenue and NOI growth but faces declining EBITDA margins and flat long-term dividend growth, tempering its income appeal. The REIT maintains an investment-grade balance sheet, modest debt-to-equity, low operator concentration, and adequate AFFO dividend coverage with a 5.6% yield. Technical momentum remains bullish, with an +8% upside forecast by 2027, though sector risks include rising labor costs and potential shifts toward home healthcare. Read the full article on Seeking Alpha

Recent updates

No updates